A young female with catastrophic antiphospholipid syndrome

Vivekanandan Senthamil Pari, Lakshmi M, Sampath Kumar, Sathyamurthy P, Sudhakar MK, Sandhya Sundaram

ABSTRACT

Introduction: Antiphospholipid syndrome is characterized by recurrent thrombosis and/or pregnancy loss with the presence of circulating antiphospholipid antibodies. Its clinical manifestations range from asymptomatic to catastrophic antiphospholipid syndrome. This condition is a rare presentation of antiphospholipid syndrome and has a very high mortality rate.

Case Report: Herein, we present a 20-year-old female patient are presented with peripheral cyanosis, computed tomography angiogram of abdomen and lower limb vessels showed arterial occlusion, and renal infarcts. She also developed seizures during hospital stay. With suspicion of vasculitis she was started on methyl prednisolone with other appropriate medications after sending blood for relevant investigations. She responded to medications, meanwhile her antiphospholipid antibody was positive with skin biopsy taken from affected limb showing microthrombi in dermal capillaries with inflammatory exudates. These features are in favor of a diagnosis of a catastrophic antiphospholipid syndrome, which will be discussed in this case report.

Conclusion: Catastrophic antiphospholipid syndrome is a rare entity occurring in 0.8–1% of patients with antiphospholipid antibody syndrome and it has a very poor prognosis. But early, aggressive treatment improves the recovery rate and requires a high degree of suspicion.

International Journal of Case Reports and Images (IJCRI)

International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties.

Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations.

IJCRI publishes Review Articles, Case Series, Case Reports, Case in Images, Clinical Images and Letters to Editor.

Website: www.ijcasereportsandimages.com
A young female with catastrophic antiphospholipid syndrome

Vivekanandan Senthamil Pari, Lakshmi M, Sampath Kumar, Sathyamurthy P, Sudhakar MK, Sandhya Sundaram

ABSTRACT

Introduction: Antiphospholipid syndrome is characterized by recurrent thrombosis and/or pregnancy loss with the presence of circulating antiphospholipid antibodies. Its clinical manifestations range from asymptomatic to catastrophic antiphospholipid syndrome. This condition is a rare presentation of antiphospholipid syndrome and has a very high mortality rate. Case Report: Herein, we present a 20-year-old female patient presented with peripheral cyanosis, computed tomography angiogram of abdomen and lower limb vessels showed arterial occlusion, and renal infarcts. She also developed seizures during hospital stay. With suspicion of vasculitis she was started on methyl prednisolone with other appropriate medications after sending blood for relevant investigations. She responded to medications, meanwhile her antiphospholipid antibody was positive with skin biopsy taken from affected limb showing microthrombi in dermal capillaries with inflammatory exudates. These features are in favor of a diagnosis of a catastrophic antiphospholipid syndrome, which will be discussed in this case report. Conclusion: Catastrophic antiphospholipid syndrome is a rare entity occurring in 0.8–1% of patients with antiphospholipid antibody syndrome and it has a very poor prognosis. But early, aggressive treatment improves the recovery rate and requires a high degree of suspicion.

Keywords: Recurrent thrombosis, Catastrophic antiphospholipid syndrome, Antiphospholipid antibodies

INTRODUCTION

Antiphospholipid syndrome (APS) is characterized by recurrent thrombosis and/or pregnancy loss with the presence of circulating antiphospholipid antibodies. A severe, rapidly progressive form characterized by involvement of at least three different organ systems within one week duration with histopathological evidence of small and large vessel occlusion is termed catastrophic antiphospholipid syndrome. It occurs in 0.8–1% of cases.
of APS as seen in various case series and has a mortality of about 50%. It presents with features suggestive of DIC (Disseminated intravascular coagulation) or TTP/HUS (thrombotic thrombocytopenic purpura/hemolytic uremic syndrome) and needs to be treated aggressively in view of the rapid progression and high mortality.

CASE REPORT

We present a case of a 20-year-old unmarried female presented to the emergency room with bluish discoloration of toes and fingers which started four days prior and was progressive, first involving the left and then the right leg toes and then fingers. It was associated with numbness and pricking type of pain. She also had breathlessness for three days which was insidious in onset, progressing from NYHA (New York Heart Association) class II to IV in three days. She also gave history of fever for four days which was low grade with no associated chills or rigors. She also had history of recurrent oral ulcers and rashes on the face on exposure to sunlight for the last six months. Her menstrual cycles were normal. She had no comorbid illnesses and no significant past medical history. On examination she was well oriented, febrile, pale, had peripheral cyanosis and bilateral pitting pedal edema. Her blood pressure was 200/110 mmHg, respiratory rate was 28 breaths/min. Chest examination revealed S3 gallop and there were crepitations heard in bilateral lung fields. Abdomen and nervous system were unremarkable. Arterial pulses distal to the femoral artery were absent in both lower limbs (Figure 1).

Baseline blood investigations revealed anemia, raised total counts, normal platelet counts, PT (partial thromboplastin time) about twice the normal with normal prothrombin time and a serum creatinine of 1.3 mg/dL with urea of 41 mg/dL. Urinalysis revealed 2+ proteinuria and no sediments. Peripheral smear showed no evidence of hemolysis. Arterial blood gas analysis showed hypoxia and metabolic acidosis with partial respiratory compensation. Chest X-ray showed bilateral pulmonary congestion. Electrocardiography had T-wave inversion in leads V1-V4 and left ventricular hypertrophy. Echocardiography was essentially normal with an ejection fraction of 60%. However, the levels of cardiac enzymes CK-MB and troponin T were slightly elevated and BNP was high (5000 ng/L). Cultures which were sent came out to be negative later. Vasculitis with acute pulmonary edema was suspected and patient was started on nitroglycerine infusion, diuretics and antihypertensives and connective tissue work up sent. Meanwhile the computed tomography (CT) angiography of lower limbs and renal vessels showed complete occlusion of anterior tibial and peroneal artery a few centimeters above the ankle with complete occlusion of dorsalis pedis bilaterally; both kidneys showed multiple wedge shaped parenchymal defects and the mid, distal segments, branches of renal arteries were small in calibre.

By the second day of admission, the patient developed severe respiratory distress and had to be ventilated, started on imipenem, low molecular weight heparin and i.v. methyl prednisolone therapy (1g/day for 5 days followed by oral prednisolone) was initiated pending the connective tissue work up reports in view of the critical condition of the patient and strong suspicion of vasculitis. On the fourth day of hospital stay the patient had one episode of generalized tonic clonic seizures, the CT scan of brain done for the same which was unremarkable and patient was switched from imipenem to piperacillin-tazobactum along with levetiracetam for the seizures. Skin biopsy was taken at the line of demarcation on the gangrenous digits to look for evidence of vasculitis/microthrombi. The connective tissue work up revealed ANA (Antinuclear antibodies), ds-DNA (double stranded DNA) and APLA (antiphospholipid antibody) positivity and ANCA (antineutrocytic cytoplasmic antibodies) were negative. Skin biopsy showed microthrombi in the dermal capillaries with surrounding inflammatory infiltrates (Figures 2–4).

Patient was gradually improving and was extubated, later switched to oral prednisolone and mycophenolate mofetil as per nephrologist’s opinion. The patient’s blood pressure was stable with oral antihypertensives and she was initiated on oral anticoagulant therapy. Amputation of the gangrenous digits/lungs was planned later. Her recovery was uneventful and was discharged on oral...
medications with advice to follow-up. On follow-up after 12 weeks repeat APLS was sent and it was positive. In this case, this is the first presentation of the patient and she came with features of limb ischemia secondary to microthrombosis, proteinuria with renal vascular changes and accelerated hypertension and she also had central nervous system involvement in the form of seizures. The above three features occurring within one week, with APLA positivity done twice more than six weeks apart, all point towards a diagnosis of catastrophic antiphospholipid syndrome (CAPS).

**DISCUSSION**

In this case, the initial differential diagnoses thought of were vasculitis, antiphospholipid syndrome with thromboses, sepsis with DIC, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.

In view of probable clinical diagnosis of vasculitis and CT angiography was suggestive of arterial occlusion she was started on steroids but later c-ANCA and p-ANCA reports turned out to be negative and skin biopsy was not suggestive of any specific vasculitis.

Another differential diagnosis considered was sepsis with disseminated intravascular coagulation since patient had thrombocytopenia leukocytosis. Hence she was initiated on broad spectrum antibiotics, but there was no evidence of bleeding or consumptive coagulopathy and microbiological cultures were negative.

We had also thought of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome but there was no history of antecedent or current diarrhea, no evidence of hemolysis such as schistocytes on peripheral smear, hyperbilirubinemia or elevated LDH and no evidence of coagulopathy either.

So, putting all the positive findings together, we have acute ischemia of all four limbs, renal ischemia, acute pulmonary edema with normal left ventricular systolic function, central nervous system involvement in the form of seizures, deranged PTT and thrombocytopenia with normal PT and no evidence of bleeding or hemolysis with negative cultures and immunopathological evidence of systemic lupus erythematosus with antiphospholipid antibody positivity (ANA and ds-DNA, APLA positive and skin biopsy showing microthrombi with no evidence of vasculitis), all event occurring within a span of one week and thus fitting into the diagnosis of catastrophic antiphospholipid syndrome.

A small subset of patients with APS can go on to rapidly progressing widespread thrombotic disease with multiorgan failure, which is called “catastrophic APS” or Asherson syndrome and has a high mortality even with treatment. Hence the problem needs to be identified early and treated aggressively.

The current criteria for classification purposes and to facilitate early recognition of catastrophic APS as suggested by Asherson et al. are given in Table 1 [1].

Catastrophic APS occurs in 0.8–1% of the patients with APLA syndrome according to various studies [2, 3]. The basic pathology of the disease process remains the same as in antiphospholipid syndrome but at an accelerated
pro-inflammatory products (e.g., tumor necrosis factor [TNF]-α, oxidants, proteases) triggering off a prothrombotic state [4]. In a meta-analysis, it was found that in about one-fourth of the patients, precipitating factors contribute to the development of catastrophic APS (infections, drugs, minor surgical procedures, anticoagulation withdrawal, etc.) and none was found in the remaining 75–80% cases [3].

The prognosis for patients with CAPS is poor with 25–50% mortality unless treated aggressively. Various modalities of treatment have been tried (no randomized trials). The combination of anticoagulation, glucocorticoids, immunosuppressants and plasma exchange with or without intravenous immune globulin (IVIG) has been associated with recovery rates ranging from 50–8% [2, 3, 5]. As per the analysis of case reports of 250 patients included in the International CAPS Registry up to February 2005 by Bucciarelli et al., systemic lupus erythematosus was identified as prognostic of a higher mortality rate. A higher recovery rate was associated with combined treatment with anticoagulants plus corticosteroids plus plasma exchange (77.8%), whereas, concomitant treatment with cyclophosphamide did not demonstrate additional benefit [5]. In patients resistant to standard therapies, case reports indicate that use of monoclonal antibodies may be beneficial. In a case report by Shapiro et al. of a patient with recurrent CAPS, despite maximal anticoagulation, immunosuppression, and plasma exchange, benefit was shown with eculizumab, a monoclonal antibody against the C5 component of complement [6]. In another case, rituximab, the B cell-depleting anti-CD20 monoclonal antibody, was successfully employed [7].

In another study, majority of patients with catastrophic APS who survived their initial illness remained free of further thromboembolic events when treated long-term with oral anticoagulants [8]. Approximately, 20–26% had recurrent APS-related events, but none had another episode of multiorgan failure. Among the recurrent thromboembolic events, 40% occurred in a perioperative period [8]. In another meta-analysis it was found that relapses occurred in about 3.2% of APLA positive patients and it was also suggested that there could be an association between MHA (microangiopathic hemolytic anemia) and relapse of catastrophic APS [9, 10].

**CONCLUSION**

Catastrophic antiphospholipid syndrome is a rare entity occurring in patients with antiphospholipid antibody syndrome and it has a very poor prognosis. But early, aggressive treatment which usually consists of a combination therapy of anticoagulation, corticosteroids, IVIG and plasma exchange, improves the recovery rate. Hence this diagnosis has to be kept in mind in a scenario of acute limb ischemia and patient started on treatment at the earliest.
Author Contributions
Vivekanandan Senthamil Pari – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Lakshmi M – Acquisition of data, Drafting the article, Final approval of the version to be published
Sampath Kumar – Acquisition of data, Drafting the article, Final approval of the version to be published
Sathyamurthy P – Acquisition of data, Drafting the article, Final approval of the version to be published
Sudhakar MK – Acquisition of data, Drafting the article, Final approval of the version to be published
Sandhya Sundaram – Acquisition of data, Drafting the article, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© Vivekanandan Senthamil Pari et al. 2014; This article is distributed under the terms of Creative Commons attribution 3.0 License which permits unrestricted use, distribution and reproduction in any means provided the original authors and original publisher are properly credited. (Please see www.ijcasereportsandimages.com/copyright-policy.php for more information.)

REFERENCES

ABOUT THE AUTHORS


Vivekanandan S is doing postgraduation, in Medicine, Sri Ramachandra Medical College & Research Institute, Porur, Chennai, Tamil Nadu, India.
Lakshmi M, DNB in Internal Medicine. She is a Senior Resident, in Department of Medicine, Sri Ramachandra Medical College & Research Institute, Chennai, Tamil Nadu, India.

Sampath Kumar, MD in Internal Medicine. He is an Assistant Professor in Department of Medicine, Sri Ramachandra Medical College & Research Institute, Porur, Chennai, Tamil Nadu, India.

Sathyamurthy, MD in Internal Medicine. He is an Associate Professor in Department of Medicine, Sri Ramachandra Medical College & Research Institute, Chennai, Tamil Nadu, India.

Sudhakar MK, MD in Internal Medicine. He is Professor & Head of Department of Medicine, Sri Ramachandra Medical College & Research Institute, Chennai, Tamil Nadu, India.

Sandhya Sundaram, MD in Pathology. She is Professor & Senior Consultant in Department of Pathology, Sri Ramachandra Medical College & Research Institute, Chennai, Tamil Nadu, India.
Edorium Journals: An introduction

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.

Mentored Review Articles (MRA)
Our academic program “Mentored Review Article” (MRA) gives you a unique opportunity to publish papers under mentorship of international faculty. These articles are published free of charges.

Most Favored Author program
Join this program and publish any number of articles free of charge for one to five years.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.